fluvastatin

05/01/2002 - "In conclusion, fluvastatin may play an important role in preventing significant oxidative stress and was shown to be safe and effective in reducing the TC, LDL-C, MDA and AI levels in dialysis patients with hypercholesterolemia. "
01/01/1997 - "In conclusion, fluvastatin as monotherapy in the treatment of hypercholesterolemia among Saudis was found to be safe, well tolerated and produced a significant improvement in the overall lipid parameters."
07/13/1995 - "In such familial hypercholesterolemic patients, the lipid-lowering efficacy of fluvastatin is related to genetic factors, and it is of interest whether the response to treatment differs from that in patients with more moderate hypercholesterolemia. "
07/13/1995 - "In conclusion, long-term treatment of hypercholesterolemia with fluvastatin at dosages of 20-40 mg daily can be considered both safe and effective."
07/01/1998 - "To assess the efficacy of fluvastatin administered every other day versus an equivalent dose given daily in patients with hypercholesterolemia. "

07/13/1995 - "Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients."
01/01/2009 - "In this study, we investigated whether lipemia-induced endothelial dysfunction can be mitigated by fluvastatin in two (immediate-release and extended-release) formulations. "
02/01/2007 - "The study comprised 37 persons, including 15 healthy volunteers and 22 patients with hyperlipidemia (TC > 200 mg/dl, LDL-C > 130 mg/dl, TG < 400 mg/dl) treated with fluvastatin XL 80 mg/d. "
04/01/2005 - "An open-label prospective cross-over trial was performed to evaluate the antioxidative effect of fluvastatin in Japanese type 2 diabetics with hyperlipidemia. "
03/01/1998 - "The study included 60 outpatients with hyperlipidemia who had received a constant dose of fluvastatin for at least 6 weeks. "

11/01/2002 - "The Lescol Intervention Prevention Study has established the effectiveness of the early use of statins in reducing recurrent events in high-risk patients with coronary heart disease post percutaneous coronary interventions. "
04/01/1999 - "Since fluvastatin was last reviewed in Drugs, trials have shown its efficacy in the secondary prevention of coronary heart disease (CHD) events and death and have expanded knowledge of its effects in primary CHD prevention and its mechanisms of activity. "
01/01/2004 - "To test the effectiveness of fluvastatin, 40-80 mg, in reducing the occurrence of cardiac and all-cause mortality in patients with coronary heart disease (CHD). "
01/01/2004 - "Fluvastatin reduces cardiac mortality in patients with coronary heart disease."
11/01/2002 - "Fluvastatin provides a useful option in treating hypercholesterolaemia in patients at high risk of coronary heart disease."

09/01/2007 - "The results from this pooled analysis found that fluvastatin was effective in reducing CVD risk in the treatment of dyslipidemia in these patients with metS."
10/15/1999 - "The effects of fluvastatin therapy on parameters of coagulation and fibrinolysis were evaluated in patients with diabetic dyslipidemia in a randomized, placebo-controlled study. "
05/01/2009 - "We aimed to assess the efficacy and safety of Monascus purpureus Went rice vs. fluvastatin therapy in the management of nephrotic dyslipidemia. "
06/01/2008 - "We aimed to assess the efficacy and safety of Monascus purpureus Went rice versus fluvastatin therapy in the management of nephrotic dyslipidemia. "
04/01/2008 - "We aimed to assess the efficacy and safety of Monascus purpureus Went rice vs. fluvastatin therapy in the management of nephrotic dyslipidemia. "

06/01/2009 - "Fluvastatin was prescribed in a fixed dose of 80 mg. The primary end point was the composite of 30-day cardiac death and MI. "
09/01/2005 - "The key determinants of cost-effectiveness included the probabilities of repeat interventions, cardiac death, the cost of fluvastatin, and the time horizon used for the evaluation. "
01/01/2004 - "Fluvastatin treatment significantly prolonged the time to cardiac death (p = 0.0174) and the time to cardiac death or nonfatal MI (p = 0.0055) compared with placebo. "
06/01/2004 - "Therefore, in the present survival analysis, we used an alternative primary end-point of cardiac death or definite nonfatal myocardial infarction (as used in other cardiac outcome trials) which was significantly reduced by Fluvastatin therapy and permits subgroup analysis. "
09/01/2005 - "A post hoc subgroup analysis of patients with diabetes from the LIPS was used to estimate the effectiveness of fluvastatin in reducing myocardial infarction, revascularization, and cardiac death. "